An F. Hoffmann-la Roche Ltd. and Hoffmann-la Roche Inc. patent describes prodrugs of serine/threonine-protein salt-inducible kinases (SIK) inhibitors. They are reported to be useful for the treatment of atherosclerosis, type 2 diabetes, giant cell arteritis, glomerulonephritis, inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis (MASH; NASH), primary sclerosing cholangitis and rheumatoid arthritis.
Avelos Therapeutics Inc. has identified substituted triazine compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.
The Council of Scientific and Industrial Research has patented hybrid peptides acting as apoptosis inducer and reactive oxygen species (ROS) production enhancers designed for use in the treatment of cancer.
Korea Research Institute of Chemical Technology has prepared and tested new serine/threonine-protein kinase LATS1 and LATS2 inhibitors reported to be useful for the treatment of sarcopenia, muscular dystrophy, inflammatory myopathy, congenital myopathy, myotonia, myofascial pain syndrome, motor neuron diseases and muscle injury.
Work at Avioris Bio Inc. has led to the discovery of proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of hypercholesterolemia.
Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have synthesized new interleukin-17A (IL-17A) inhibitors described as potentially useful for the treatment of inflammatory disorders.
Zhejiang Pantheon Innovation Pharmaceutical Co. Ltd. has disclosed prodrugs of an NLRP3 inflammasome inhibitor compound. They are reported to be useful for the treatment of cancer and inflammation.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have discovered GTPase KRAS mutant inhibitors, particularly G12V, G12D and G12C mutant inhibitors. They are reported to be useful for the treatment of cancer.
RSS